What disease is Lynparza used for?

Olaparib, as a highly effective oral PARP inhibitor, is gradually becoming an important drug for the treatment of cancers closely related to BRCA gene mutations.

Olaparib has shown excellent results in the treatment of ovarian cancer. Especially for patients with BRCA1 or BRCA2 gene mutations, olaparib can be used as maintenance treatment after initial chemotherapy, which can significantly delay disease recurrence and extend progression-free survival (PFS), thus improving the overall survival time of patients. For example, in the famous SOLO-1 trial, the median PFS of the olaparib treatment group was significantly better than that of the placebo group, fully proving its efficacy.

Olaparib also plays an important role in the treatment of breast cancer. It is particularly suitable for patients with advanced breast cancer with BRCA gene mutations who have progressed on previous treatments. Clinical studies have shown that olaparib can effectively control the disease, delay disease progression, and improve patients' treatment response rate.

Olaparib also performs well in the treatment of castration-resistant prostate cancer (CRPC). Especially for CRPC patients with BRCA1/2 gene mutations, olaparib can significantly prolong PFS and help patients delay disease progression. The PROfound trial further confirmed the therapeutic advantages of olaparib in these patients.

In addition to the cancer types listed above, olaparib is also used in some cases to treat pancreatic cancer associated withBRCA mutations. Although its primary use is in ovarian and breast cancer, olaparib may also provide an effective treatment option for certain patients with pancreatic cancer.

Olaparib, as a specific drug for BRCA gene mutation-related cancers, interferes with cancer cells by inhibiting PARP enzymesDNA repair mechanism has significantly improved the therapeutic effect of these cancers and the quality of life of patients.